AstraZeneca's $4.5 billion investment is just the beginning. More pharmaceutical giants are expected to follow suit, creating a sustained boom for companies that build and equip these advanced facilities.
Government incentives and supply chain security concerns are driving pharmaceutical onshoring. This creates predictable, long-term demand for the specialised companies in this group.
Building pharmaceutical facilities takes years and requires cutting-edge technology. These companies are positioned to benefit from a sustained capital expenditure cycle as the industry reshores production.
AstraZeneca's $4.5 billion Virginia plant investment signals a major shift towards domestic pharmaceutical manufacturing. This onshoring trend, driven by government incentives and supply chain security needs, creates sustained demand for the specialised companies that build and equip these advanced facilities.
This theme captures a multi-year capital expenditure cycle as pharmaceutical giants follow AstraZeneca's lead. The companies selected provide essential services like specialised construction, industrial automation, process controls, and life sciences instrumentation needed for these complex facilities.
These companies were handpicked as the key suppliers and builders positioned to benefit from pharmaceutical reshoring. They represent the essential infrastructure providers, from engineering firms to automation specialists, that make domestic drug production possible.
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Aggregate and breakdown of market capitalisation for the 'Pharma's American Factory Boom' stock basket.
AZN: $266.90B
J: $18.58B
FLR: $7.03B
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
Analysten erwarten im Durchschnitt, dass die Werte dieser Gruppe im nächsten Jahr um 53.63 % zulegen.
14 von 16 Werten dieser Gruppe werden von professionellen Analysten mit „Kaufen“ bewertet.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
Wenn Sie in diese Werte investieren:
In 12 Monaten könnte der Wert betragen:
+53.63%
Erfahren Sie alles über diesen Aktienkorb. Lesen Sie unseren ausführlichen Artikel zu seinen Risiken und seinem Potenzial.
Vollständige Analyse lesen
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
